h*********r
发帖数: 2844 | 1 那个oxford nanopore 一年前吹了很大的牛，现在还没任何动静，也没数据。nanopore
方面的研究很多。谁能说说这个技术feasible 吗？有没有什么终极技术瓶颈？ | b******n
发帖数: 4225 | 2 我觉得还需要市场考验
牛刚开始都吹，二阶导数三阶导数的提升（差别）都可以理论上分析出来
但是实际上怎么样要等等看
nanopore
【在 h*********r 的大作中提到】
: 那个oxford nanopore 一年前吹了很大的牛，现在还没任何动静，也没数据。nanopore
: 方面的研究很多。谁能说说这个技术feasible 吗？有没有什么终极技术瓶颈？
| s********n
发帖数: 2939 | | l**********1
发帖数: 5204 | 4 cited from OX dot ac dot uk
6 gene sequencing test for cancer patients on the NHS
Health
Science 25 Mar 13
The first multi-gene test that can help predict cancer patients' responses
to treatment using the latest DNA sequencing techniques has been launched in
the NHS, thanks to a partnership between scientists at the University of
Oxford and Oxford University Hospitals NHS Trust.
The test detects mutations across 46 genes in cancer cells, mutations which
may be driving the growth of the cancer in patients with solid tumours. The
presence of a mutation in a gene can potentially determine which treatment a
patient should receive.
The researchers say the number of genes tested marks a step change in
introducing next-generation DNA sequencing technology into the NHS, and
heralds the arrival of genomic medicine with whole genome sequencing of
patients just around the corner.
The new £300 test could save significantly more in drug costs by
getting patients on to the right treatments straightaway, reducing harm from
side effects as well as the time lost before arriving at an effective
treatment.
The many-gene sequencing test has been launched through the National
Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
, a collaboration between Oxford University Hospitals NHS Trust and Oxford
University.
The BRC Molecular Diagnostics Centre carries out the test. The lab, based at
Oxford University Hospitals, covers all cancer patients in the Thames
Valley area. But the scientists are looking to scale this up into a truly
national NHS service through the course of this year.
omitted stuff
http://www.ox.ac.uk/media/news_stories/2013/130325.html | h*********r
发帖数: 2844 | 5 文中"the latest dna sequencing technology" 是nanopore技术吗？为什么这么偷偷
摸摸不肯明说泥？
in
which
The
【在 l**********1 的大作中提到】
: cited from OX dot ac dot uk
: 6 gene sequencing test for cancer patients on the NHS
: Health
: Science 25 Mar 13
: The first multi-gene test that can help predict cancer patients' responses
: to treatment using the latest DNA sequencing techniques has been launched in
: the NHS, thanks to a partnership between scientists at the University of
: Oxford and Oxford University Hospitals NHS Trust.
: The test detects mutations across 46 genes in cancer cells, mutations which
: may be driving the growth of the cancer in patients with solid tumours. The
| l**********1
发帖数: 5204 | 6 patent concern at this season
【在 h*********r 的大作中提到】
: 文中"the latest dna sequencing technology" 是nanopore技术吗？为什么这么偷偷
: 摸摸不肯明说泥？
:
: in
: which
: The
| b****r
发帖数: 17995 | 7 那会那么hyper，然后突然一点动静都没有这么久，不得不让人生疑
不过 这个原理还是完全符合常识的 ，即使他们不行，我觉得迟早有人会实现的 | l**********1
发帖数: 5204 | 8 Illumina won first round Competition before QE2 of 2013
Genomics Conference Illustrates that Illumina is Outpacing the Competition
Ivan Deryugin
March 15, 2013
On the evening of March 14, Illumina (ILMN) announced that a federal jury
found it guilty of infringing a patent held by Syntrix Biosystems relating
to the company’s BeadChip product line, fining Illumina $96 million based
on a 6% royalty on all BeadChip sales between 2005 and September 2012 (
Syntrix’s lawsuit was filed in November 2010).
AGBT 2013: Highlighting Illumina’s Strengths
Life Technologies, arguably Illumina’s largest and key competitor, provided
updates on its own technology, the Ion Proton system, including its new Ion
Proton PII system. Admittedly, Life has made a good deal of progress in
resolving several issues relation to its sequencing franchise, namely the
issue of homopolymer errors, which are a key issue when it comes to Life’s
semiconductor-based sequencing process (and Roche’s sequencing technology
as well). However, Life’s Ion Proton PII system, seen by many as a
meaningful competitor to Illumina, has been delayed. Life originally
expected to launch the Ion Proton PII system in Q4 2012, but the system is
now set to launch in mid-2013,
Oxford Nanopore’s systems. However, the company’s CTO Clive Brown did
state that the company’s systems will be delayed by about 5 months due to
quality issues relating to one of the company’s sensors. In addition,
Oxford Nanopore is working to address issues regarding the accuracy of its
sequencing systems, with a goal of lowering its error rate down to 1% from a
current 4%.
The delays at Life Technologies and Oxford Nanopore do more than give
Illumina months of additional runway to update its own sequencing systems
and make progress in developing new technologies.
//propthink.com/genomics-conference-illustrates-that-illumina-is-
outpacing-the-competition/5472
【在 l**********1 的大作中提到】
: patent concern at this season
|
|
|
